Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as a ...
Fourth Quarter HighlightsRevenue was $779 million, up 5.9%, and up 5.2% on an organic constant currency (OCC) basis, a non-GAAP measure.Net ...
Fourth Quarter Highlights Revenue was $779 million, up 5.9%, and up 5.2% on an organic constant currency (OCC) basis, a non-GAAP measure.Net income was $197 million, down 6.2% due to gains recognized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results